Welcome to our dedicated page for Bayer A G news (Ticker: BAYZF), a resource for investors and traders seeking the latest updates and insights on Bayer A G stock.
The BAYZF news page on Stock Titan aggregates recent announcements and press releases related to Bayer AG, a global life science company with core competencies in health care and nutrition. Investors and observers can use this feed to follow how Bayer communicates about its pharmaceutical pipeline, radiology developments, crop science launches and broader corporate strategy.
Recent Bayer news has highlighted updates on its Pharmaceuticals Division, including growth plans built around high-value products and a modality-rich pipeline in oncology, cardiology, neurology, immunology and women’s health. Releases describe pivotal approvals, regulatory milestones, and clinical data from programs in areas such as stroke prevention, heart failure, chronic kidney disease, prostate cancer, lung cancer and menopause-related vasomotor symptoms.
The news flow also covers Bayer’s activities in radiology and molecular imaging, such as clinical results for an investigational low-dose MRI contrast agent and the acquisition of investigational PET and SPECT tracers for diagnosing cardiac amyloidosis. In addition, company communications report collaborations in advanced modalities like cell and gene therapy and siRNA-based treatments, as well as progress in rare kidney diseases including Alport Syndrome.
Beyond human health, Bayer’s crop science releases describe new insecticides and seed treatments for crops such as canola and pulses, illustrating its role in agricultural inputs and food production. Together, these updates provide context on how Bayer pursues its stated mission of “Health for all, Hunger for none” across pharmaceuticals, diagnostics and agriculture. For anyone tracking BAYZF, this news page offers a centralized view of the company’s reported clinical milestones, product launches, partnerships and strategic initiatives over time.
Bayer (OTC:BAYRY) announced that the FDA has accepted its New Drug Application (NDA) for gadoquatrane, a novel low-dose contrast agent for magnetic resonance imaging (MRI). The contrast agent is designed for imaging the central nervous system and other body regions in both adults and pediatric patients, including neonates.
The submitted dose of 0.04 mmol gadolinium per kilogram body weight represents a 60% reduction in gadolinium compared to current macrocyclic gadolinium-based contrast agents (GBCAs). The submission is supported by positive data from the Phase III QUANTI studies, and similar applications are under review in Japan, the European Union, and other countries.
Monsanto (OTC:BAYRY) has announced agreements in principle to resolve PCB-related litigation cases involving over 200 plaintiffs from the Sky Valley Education Center in Washington state. The settlement excludes nine prior adverse verdicts (involving 49 plaintiffs) that remain under appeal.
The settlement costs are covered by the PCB litigation provision taken in Q2 2025. The company is pursuing a strategy to contain litigation risks by the end of 2026 and has filed a complaint in Missouri to enforce indemnity contracts signed in 1972 by former electrical manufacturing customers.
Bayer (OTC:BAYRY) has announced the U.S. launch of Aspirina, its leading pain relief product in Mexico, targeting the growing Hispanic market. The strategic expansion aims to serve the Hispanic population, which currently represents 19% of the U.S. population and is projected to reach 28% by 2060.
Aspirina holds impressive market metrics in Mexico, including a 99% awareness rate and 67% regular consumer usage. The product will be available at select Walmart and Walgreens locations, leveraging Bayer's 125-year legacy in aspirin manufacturing and the strong cultural connection among Hispanic consumers, with 70% maintaining strong ties to their country of origin.
The Fears Nachawati law firm is urging a federal judge to reject a proposed settlement between Bayer (OTCMKTS: BAYZF, BAYRY) and consumers seeking reimbursement for Roundup. They allege that the settlement could limit cancer victims' ability to seek justice. Representing over 4,000 cancer victims, the firm raises concerns about collusion due to generous legal fees and ambiguous language that may protect Monsanto from damages. Previous attempts at a similar settlement were blocked by the JPML. Notably, several trials have found that Roundup exposure causes cancer, leading to multimillion-dollar verdicts.
A panel has denied Bayer's request to settle lawsuits linked to its Roundup herbicide, impacting ongoing multidistrict litigation affecting thousands of cancer victims. The Judicial Panel on Multidistrict Litigation ruled on Oct. 8, transferring the case to U.S. District Judge Vince Chhabria, who has previously rejected settlements from Monsanto. Legal representatives criticized Bayer's actions as an attempt to limit justice for cancer victims, emphasizing the judge's capability to handle such cases. Three prior bellwether trials have ruled against Bayer, affirming that Roundup exposure caused cancer.